Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC)

Autor:	Stina M. Singel, Matthew Wongchenko, Rebecca Dent, Daniel J. Maslyar, Mafalda Oliveira, Amy V. Kapp, Sung-Bae Kim, Sibel Blau, Marc Espié, José Baselga, Cristina Saura, Steven J. Isakoff, Seock-Ah Im, Wai Y. Chan, Antoinette R. Tan
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty business.industry First line Locally advanced food and beverages Placebo Ipatasertib humanities Double blind 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Paclitaxel chemistry 030220 oncology & carcinogenesis Internal medicine Clinical endpoint medicine business Triple-negative breast cancer
Zdroj:	Journal of Clinical Oncology. 36:1008-1008
ISSN:	1527-7755 0732-183X
Popis:	1008Background: In LOTUS (NCT02162719), adding the oral AKT inhibitor IPAT to first-line PAC for mTNBC improved progression-free survival (PFS; primary endpoint) [Kim, Lancet Oncol 2017]. The strat...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::88b53c4c0eb2d844a14e8aef770117cf https://doi.org/10.1200/jco.2018.36.15_suppl.1008 Zobrazit plný text záznamu